V for DME
More recent research suggests that vitrectomy works in DME – and that it might be the cost-effective treatment we’re looking for
J. Fernando Arevalo |
Diabetic macular edema (DME) is a major cause of visual impairment. It is currently treated with anti-VEGF therapy – but it might not stay that way for much longer. As private insurers and national health care systems struggle to manage the escalating costs associated with monthly anti-VEGF therapy, it is obvious that a long-lasting, reasonably priced treatment for DME is needed – and I think vitrectomy could be the answer.
Vitrectomy removes traction, eliminates vasoproliferative factors, and improves oxygenation. But despite several retrospective and prospective studies showing that vitrectomy significantly decreases DME, it is not yet supported by good clinical evidence. Many of the existing studies lack consistent enrollment criteria, control groups, and standardized measurements of visual acuity (VA), as well as the use of more advanced OCT technology.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.